127 related articles for article (PubMed ID: 2893394)
1. Effect of esmolol on the ventricular fibrillation threshold.
Wallis DE; Wedel VA; Scanlon PJ; Euler DE
Pharmacology; 1988; 36(1):9-15. PubMed ID: 2893394
[TBL] [Abstract][Full Text] [Related]
2. Antifibrillatory effect of esmolol alone and in combination with lidocaine.
Tisdale JE; Sun H; Zhao H; Fan CD; Colucci RD; Kluger J; Chow MS
J Cardiovasc Pharmacol; 1996 Mar; 27(3):376-82. PubMed ID: 8907799
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of a beta-adrenergic receptor antagonist, propranolol, in preventing ischaemic ventricular fibrillation: dependence on heart rate and ischaemia duration.
Aupetit JF; Frassati D; Bui-Xuan B; Freysz M; Faucon G; Timour Q
Cardiovasc Res; 1998 Mar; 37(3):646-55. PubMed ID: 9659448
[TBL] [Abstract][Full Text] [Related]
4. Effects of metoprolol, alone and in combination with lidocaine, on ventricular fibrillation threshold: comparison with atenolol, propranolol, and pindolol.
Coram WM; Olson RW; Beil ME; Cabot CF; Weiss GB
J Cardiovasc Pharmacol; 1987 May; 9(5):611-21. PubMed ID: 2439844
[TBL] [Abstract][Full Text] [Related]
5. Mechanism of the effect of bretylium on the ventricular fibrillation threshold in dogs.
Euler DE; Scanlon PJ
Am J Cardiol; 1985 May; 55(11):1396-401. PubMed ID: 3993577
[TBL] [Abstract][Full Text] [Related]
6. Comparative effects of antiarrhythmic drugs on the ventricular fibrillation threshold.
Euler DE; Scanlon PJ
J Cardiovasc Pharmacol; 1988 Mar; 11(3):291-8. PubMed ID: 2452921
[TBL] [Abstract][Full Text] [Related]
7. Maternally administered esmolol produces fetal beta-adrenergic blockade and hypoxemia in sheep.
Eisenach JC; Castro MI
Anesthesiology; 1989 Nov; 71(5):718-22. PubMed ID: 2573294
[TBL] [Abstract][Full Text] [Related]
8. The effects of esmolol and dexmedetomidine on myocardial oxygen consumption during sympathetic stimulation in dogs.
Willigers HM; Prinzen FW; Roekaerts PM
J Cardiothorac Vasc Anesth; 2006 Jun; 20(3):364-70. PubMed ID: 16750737
[TBL] [Abstract][Full Text] [Related]
9. Effects of veratrine on the in situ dog heart: evidence for increased ventricular fibrillation threshold.
Arbel ER; Glick G
J Pharmacol Exp Ther; 1979 Feb; 208(2):314-8. PubMed ID: 762666
[TBL] [Abstract][Full Text] [Related]
10. Pharmacodynamics and onset of action of esmolol in anesthetized dogs.
Quon CY; Gorczynski RJ
J Pharmacol Exp Ther; 1986 Jun; 237(3):912-8. PubMed ID: 2872328
[TBL] [Abstract][Full Text] [Related]
11. Antifibrillatory effects of class III antiarrhythmic drugs: comparative study with flecainide.
Usui M; Inoue H; Saihara S; Sugimoto T
J Cardiovasc Pharmacol; 1993 Mar; 21(3):376-83. PubMed ID: 7681497
[TBL] [Abstract][Full Text] [Related]
12. Electrophysiologic, cardiohemodynamic and beta-blocking actions of a new ultra-short-acting beta-blocker, ONO-1101, assessed by the in vivo canine model in comparison with esmolol.
Sugiyama A; Takahara A; Hashimoto K
J Cardiovasc Pharmacol; 1999 Jul; 34(1):70-7. PubMed ID: 10413070
[TBL] [Abstract][Full Text] [Related]
13. Myocardial protection: the efficacy of an ultra-short-acting beta-blocker, esmolol, as a cardioplegic agent.
Bessho R; Chambers DJ
J Thorac Cardiovasc Surg; 2001 Nov; 122(5):993-1003. PubMed ID: 11689806
[TBL] [Abstract][Full Text] [Related]
14. Pulmonary reactivity to methacholine during beta-adrenergic blockade: propranolol versus esmolol.
Tobias JD; Sauder RA; Hirshman CA
Anesthesiology; 1990 Jul; 73(1):132-6. PubMed ID: 1972872
[TBL] [Abstract][Full Text] [Related]
15. Calcium antagonists and prevention of ventricular fibrillation induced by transient or persistent ischemia.
Timour Q; Bui-Xuan B; Aupetit JF; Freysz M; Evreux JC; Faucon G
Jpn Heart J; 1997 Mar; 38(2):237-51. PubMed ID: 9201111
[TBL] [Abstract][Full Text] [Related]
16. Effects of stress and beta 1 blockade on the ventricular depolarization gradient of the rate modulating pacemaker.
Singer I; Brennan AF; Steinhaus B; Maldonado C; Kupersmith J
Pacing Clin Electrophysiol; 1991 Mar; 14(3):460-9. PubMed ID: 1708877
[TBL] [Abstract][Full Text] [Related]
17. An enantiomerically pure formulation of esmolol attenuates hypotension and preserves heart rate control in dogs.
McKee JS; Rabinow BE; Daller JR; Brooks BD; Baumgartner B; Rohatgi P
Anesthesiology; 2014 Dec; 121(6):1184-93. PubMed ID: 25105423
[TBL] [Abstract][Full Text] [Related]
18. Esmolol: effects on isoprenaline- and exercise-induced cardiovascular stimulation in conscious dogs.
Fischer G; Grohs JG; Raberger G
Can J Physiol Pharmacol; 1990 Oct; 68(10):1322-8. PubMed ID: 1981854
[TBL] [Abstract][Full Text] [Related]
19. Esmolol for potentiation of nitroprusside-induced hypotension: impact on the cardiovascular, adrenergic, and renin-angiotensin systems in man.
Edmondson R; Del Valle O; Shah N; Wong G; Dwyer D; Matarazzo D; Thorne A; Coffey C; Bedford R
Anesth Analg; 1989 Aug; 69(2):202-6. PubMed ID: 2569849
[TBL] [Abstract][Full Text] [Related]
20. Time dependency of ventricular fibrillation thresholds determined using trains of stimuli.
Winkle RA; Jaillon P; Griffin JC; Schnittger I
Am J Physiol; 1980 Oct; 239(4):H457-H463. PubMed ID: 7425137
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
